Improving the overall health of the pharmaceutical supply chain and the patients it serves.

East Norriton, PA -- (ReleaseWire) -- 11/06/2017 -- BlockRx, the first ICO geared to secure the Pharmaceutical industry and incentivize positive patient outcomes, announces internet marketing pioneer Ryan Scott is joining as Executive Advisor.

"The BlockRx project has great potential to impact not just the pharmaceutical industry, but healthcare outcomes as a whole," says Mr. Scott. "It is a unique opportunity that incentivizes both patients and business to share their data in a cryptographically secure way, leveraging the power of blockchain technology. The end goal is better health outcomes for patients, and improved business process and traceability for the Pharma industry."

Ryan Scott is an entrepreneur, social impact investor, humanist, philanthropist and online marketing pioneer, having developed and patented the double opt-in email methodology. After selling NetCreations in 2001 for $111 million, Ryan became the founder of Causecast and a an angel investor and advisor alongside Sequoia Capital, Mark Cuban, News Corp, CBS Corporation, Elon Musk, and Burda Media, in a number of companies such as Inside, Tesla, CrowdFunder, Tiltify, Lottery.com, Principle Power, Signum Biosciences, Greener World Media, Sierra Nevada Solar.

"With Mr. Scott joining the BlockRx Project as an Executive Advisor, we draw not only from his experience, but a shared vision that an incentivized Blockchain will improve the Pharma supply chain." explains Gordon Tampol, CEO of iSolve. "The global pharma market is an $800 billion industry, while the counterfeited medicine business is estimated between $75-200 billion with a significant impact on patients. The BlockRx Pharma Ecosystem will provide the transparency, security and incentives needed to shield patients."

The BlockRx Pharma Ecosystem is a robust solution incorporating Hyperledger Sawtooth, an open source blockchain framework hosted by the Linux Foundation, and spearheaded by Intel; the BlockRx Token for blockchain entries and data exchange; and iSolve's Advanced Digital Ledger Technology (ADLT) to integrate legacy systems with the blockchain.

The BlockRx Token will be the primary means of rewarding trade partners and consumers for utilizing the blockchain as a vehicle for managing data entries pertaining to drug development and logistics. The BlockRx Token will be used to provide valuable information to other trusted partners through the BlockRx Pharma Ecosystem and can also serve as a medium of exchange for the acquisition of intellectual property, services, and data exchange. See the BlockRx white paper for complete details.

About BlockRx ICO
The BlockRx Initial Coin Offering (ICO) is scheduled to run until January 31, 2017. During this time BlockRx invites investors to become better acquainted with the company before they choose to support the project. The ICO period is set for a limited time.

Visit http://www.BlockRx.com for details.

About BlockRx™
BlockRx™ is a series of initiatives by iSolve which leverage the blockchain and iSolve's Advanced Digital Ledger Technology™ (ADLT™). The platform is a comprehensive solution to fully integrate Life Science Researchers, BioPharma Companies, Medical Device Manufacturers, Retailers and Healthcare Providers to improve patient outcomes.

About iSolve
iSolve is dedicated to supporting organizations throughout the drug development lifecycle. By developing cutting edge blockchain solutions that help align company initiatives with strategic partners, we will help organizations achieve their corporate goals and expand their enterprise.

Media Contact:
Ryan Scott can be reached at https://www.linkedin.com/in/theryanscott/.
Please submit all press inquiries and interview requests to press@blockRx.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Improving the overall health of the pharmaceutical supply chain and the patients it serves.

East Norriton, PA -- (ReleaseWire) -- 10/09/2017 -- BlockRx has announced the launch of its groundbreaking BlockRx Token ICO fundraising campaign, which opened to the public on September 21, 2017. Part of the premier Dubai ICO Crypto Bazar Event, BlockRx has been garnering attention and commitments from major Global investors, including representatives from the UAE Central Bank.

The BlockRx Token is one of the critical branches of the three-pronged BlockRx Pharma Ecosystem solution, alongside iSolve's ADLT™ platform, and the Hyperledger Sawtooth, an open source blockchain framework hosted by the Linux Foundation initially contributed by Intel.

Today, the global pharma market is approximately an $800 billion industry, with projected growth to $1.12 trillion by 2022. The counterfeit medicine business, currently estimated between $75-200 billion annually by the World Customs Organization, is a fast-growing, global epidemic with significant human and financial costs.

Furthermore, the rising cost of healthcare is outpacing the increase in personal income. The average patient struggles to maintain a balance between healthcare costs and effective outcomes. In the United States "Patient payments now account for 35% of provider revenue… by comparison, in 2000 patients paid just 5% of healthcare provider revenue," according to the U.S. Commerce Department's Bureau of Economic Analysis.

"The urgency for a cutting-edge solution to combat counterfeiting and reduce medical costs is more prevalent than at any other time," explains Gordon Tampol, CEO of iSolve. "This BlockRx Token is a critical utility enabling the underlying platform to optimize and secure a decentralized pharmaceutical supply chain while empowering patients with the ability to manage and share their health data. Patients can earn BlockRx Tokens in exchange for their data on their terms, and the Tokens can in turn be used to reduce the costs of medicines, co-pays, and insurance premiums."

The BlockRx Pharma Ecosystem is a robust solution incorporating Hyperledger Sawtooth by Intel, a high-performance enterprise blockchain; the BlockRx Token for blockchain entries and data exchange; and iSolve's Advanced Digital Ledger Technology (ADLT) to integrate legacy systems with the blockchain.

The BlockRx Token will be the primary means of rewarding trade partners and consumers for utilizing the blockchain as a vehicle for managing data entries pertaining to drug development and logistics. The BlockRx Token will be used to provide valuable information to other trusted partners through the BlockRx Pharma Ecosystem and can also serve as a medium of exchange for the acquisition of intellectual property, services, and data exchange. See the BlockRx white paper for complete details.

BlockRx has made available 120 million digital tokens called the BlockRx Token (BKRx).

About BlockRx ICO
The BlockRx Initial Coin Offering (ICO) is scheduled to run until October 19 2017. During this time BlockRx invites investors to become better acquainted with the company before they choose to support the project. The ICO period is set for a limited time.

Visit www.BlockRx.com for details.

About BlockRx™
BlockRx™ is a series of initiatives by iSolve which leverage the blockchain and iSolve's Advanced Digital Ledger Technology™ (ADLT™). The platform is a comprehensive solution to fully integrate Life Science Researchers, BioPharma Companies, Medical Device Manufacturers, Retailers and Healthcare Providers to improve patient outcomes.

About iSolve
iSolve is dedicated to supporting organizations throughout the drug development lifecycle. By developing cutting edge blockchain solutions that help align company initiatives with strategic partners, we will help organizations achieve their corporate goals and expand their enterprise.

Media Contact:

Please submit all press inquiries and interview requests to press@blockrx.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Combatting the US $220 billion counterfeit medicine problem with a dose of blockchain.

East Norriton, PA -- (ReleaseWire) -- 08/17/2017 -- BlockRx has announced its partnership with Intel®, one of the world's largest technology companies, and YourEncore, the industry's leading provider of proven expertise in the life sciences market, amidst the launch of its groundbreaking BlockRx Token ICO fundraising campaign, open to the public in September 2017. The BlockRx Token is one of the critical branches of the three-pronged BlockRx Pharma Ecosystem solution alongside iSolve's ADLT™ platform and the Sawtooth Blockchain by Intel.

Today, the global pharma market is approximately a US$800 billion industry, with projected growth to $1.12 trillion by 2022 and it has a serious disease impacting patient safety. The counterfeit medicine business, currently estimated between US $75-200 billion annually by the World Customs Organization, is a fast-growing, global epidemic with significant human and financial costs:

- World Health Organization (WHO) estimates 10% to 30% of medicines distributed are counterfeit

- More than 100,000 lives are lost annually

- EU is predicting 90,000 direct and indirect job losses

"The urgency for a cutting-edge solution to combat this epidemic is more prevalent than at any other time; this is why the pharmaceutical industry needs the BlockRx Pharma Ecosystem," explains Gordon Tampol, CEO of iSolve. "This ecosystem is the underlying platform for managing security, verification, distribution and decentralization across the pharmaceutical supply chain."

The BlockRx Pharma Ecosystem is a robust solution incorporating Sawtooth by Intel, a high-performance enterprise blockchain; the BlockRx Token for blockchain entries and data exchange; and iSolve's Advanced Digital Ledger Technology (ADLT) to integrate legacy systems with the blockchain.

The BlockRx Token will be the primary means of rewarding trade partners and consumers for utilizing the blockchain as a vehicle for managing data entries pertaining to drug development and logistics. The BlockRx Token will be used to provide valuable information to other trusted partners through the BlockRx Pharma Ecosystem and can also serve as a medium of exchange for the acquisition of intellectual property (IP), services, and data exchange. See the BlockRx white paper for complete details.

BlockRx will make available 120 million digital tokens called the BlockRx Tokens (BRx).

BlockRx ICO and Token Pre-sale
The BlockRx Initial Coin Offering (ICO) and token pre-sale stage are scheduled to run for two months starting August 2017. During this time BlockRx invites investors to become better acquainted with the company before they choose to support the project. The ICO period is set for a limited time.

Visit http://www.BlockRx.com for details.

About BlockRx™
BlockRx™ is a series of initiatives by iSolve which leverages the blockchain and iSolve's Advanced Digital Ledger Technology™ (ADLT™). The platform is a comprehensive solution to fully integrate Life Science Researchers, BioPharma Companies, Medical Device Manufacturers, Retailers and Healthcare Providers to improve Patient Outcomes.

For more information visit http://www.BlockRx.com, follow @BlockRxProject, or join us on http://www.BlockRx.slack.com.

About iSolve
iSolve is dedicated to supporting organizations throughout the drug development lifecycle. By developing cutting edge blockchain solutions that help align company initiatives with strategic partners, we will help organizations achieve their corporate goals and expand their enterprise.

For more information, visit http://www.isolve.io.

Media Contact:
Please submit all press inquiries and interview requests to press@blockRx.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm